Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Deltex Homolog 4 Antibodies:
anti-Mouse (Murine) Deltex Homolog 4 Antibodies:
anti-Rat (Rattus) Deltex Homolog 4 Antibodies:
Go to our pre-filtered search.
Notch (show NOTCH1 Antibodies) is ligand activated and undergoes DTX4-mediated ubiquitylation and bilateral endocytosis before ADAM10 (show ADAM10 Antibodies) processing
FLT3 (show FLT3 Antibodies) cell-surface expression did not vary by FLT3 (show FLT3 Antibodies) mutational status, but high FLT3 (show FLT3 Antibodies) expression was strongly associated with KMT2A (show MLL Antibodies) rearrangements. Our study found that there was no prognostic significance of FLT3 (show FLT3 Antibodies) cell surface expression in pediatric Acute Myeloid Leukemia (show BCL11A Antibodies)
DNA mutational analysis in FLT3 (show FLT3 Antibodies) in acute myeloid leukemia (show BCL11A Antibodies).
data confirm MLL (show MLL Antibodies)-PTD (show BCS1L Antibodies) and, to a lesser extent, FLT3 (show FLT3 Antibodies)-ITD as common events in +11 AML (show RUNX1 Antibodies).6, 7, 8 However, the high mutation frequencies of U2AF1 (show U2AF1 Antibodies) and genes involved in methylation (DNMT3A (show DNMT3A Antibodies), IDH2 (show IDH2 Antibodies)) have hitherto not been reported in +11 AML (show RUNX1 Antibodies)
The cytokine Fms-like tyrosine kinase 3 ligand is an important regulator of hematopoiesis. Its receptor, Flt3 (show FLT3 Antibodies), is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages. [review]
FLT3 (show FLT3 Antibodies) amplification in solid cancers is infrequently observed using targeted genomic profile, as yet, FLT3 (show FLT3 Antibodies) amplification does not seem to be an actionable target or a proper biomarker for FLT3 (show FLT3 Antibodies) inhibitor sensitivity.
FLT3 (show FLT3 Antibodies) has a role in cytarabine transport by SLC29A1 (show SLC29A1 Antibodies) in pediatric acute leukemia
Data indicate a pathway MYSM1 (show MYSM1 Antibodies)/miR (show MLXIP Antibodies)-150/FLT3 (show FLT3 Antibodies) that inhibits proliferation of B1a cells, which may be involved in the pathogenesis of systemic lupus erythematosus (SLE).
findings confirm that FLT3 (show FLT3 Antibodies)-ITD-location influences disease biology and leads to changes in global gene expression. In our model, ITD-location alters proliferative capacity and sensitivity to FLT3 (show FLT3 Antibodies)-TKI-treatment in vivo
a decision analysis comparing allo-HCT vs chemotherapy in first complete remission for patients with cytogenetically intermediate-risk acute myeloid leukemia (show BCL11A Antibodies), depending on the presence or absence of FLT3 (show FLT3 Antibodies)-ITD), NPM1 (show NPM1 Antibodies), and CEBPA (show CEBPA Antibodies) mutations showed that allo-HCT was a favored postremission strategy in patients with FLT3 (show FLT3 Antibodies)-ITD, and chemotherapy was favored in patients with biallelic CEBPA (show CEBPA Antibodies) mutations.
The results indicate that DTX4 stable knockdown inhibits adipogenesis of 3T3-L1 cells through inhibiting C/EBPalpha (show CEBPA Antibodies) and PPARgamma (show PPARG Antibodies), arresting mitotic clonal expansion and regulating Wnt (show WNT2 Antibodies) signaling pathway.
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
, FL cytokine receptor
, fetal liver kinase 2
, fms-like tyrosine kinase 3
, growth factor receptor tyrosine kinase type III
, receptor-type tyrosine-protein kinase FLT3
, stem cell tyrosine kinase 1
, deltex 4 homolog
, E3 ubiquitin-protein ligase DTX4
, RING finger protein 155
, protein deltex-4
, deltex 4, E3 ubiquitin ligase
, deltex homolog 4
, LOW QUALITY PROTEIN: E3 ubiquitin-protein ligase DTX4